お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
953774

急性骨髄性白血病 (AML):AMLの治療環境の変化 、エグゼクティブサマリー (2020年)

Acute Myeloid Leukemia (AML) - The Changing Landscape of Treatment in AML, Executive Deck 2020

出版日: | 発行: Mellalta Meets LLP | ページ情報: 英文 235 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.49円
急性骨髄性白血病 (AML):AMLの治療環境の変化 、エグゼクティブサマリー (2020年)
出版日: 2020年08月04日
発行: Mellalta Meets LLP
ページ情報: 英文 235 Pages
納期: 即納可能 即納可能とは
担当者のコメント
急性骨髄性白血病 (AML)市場に着目した最新調査レポートです。新たな治療法、最新のアンメットニーズ、及び市場動向をまとめております。原本で事前に内容をご案内させていただきますので、まずはお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

急性骨髄性白血病 (AML) は、血液幹細胞から発生するがんです。一般に、急性骨髄性白血病、急性骨髄性白血病、急性骨髄芽球性白血病、急性顆粒球性白血病、または急性非リンパ性白血病 (ANLL) として知られています。 世界のAMLの発症件数は、2019年に105,842件、2030年には119,247件に達する見通しで、この間の潜在的な成長率は1.09%と推計されています。

当レポートでは、急性骨髄性白血病 (AML) の疫学的動向と治療薬の開発状況について分析し、国際会議での報告内容などを踏まえつつ、疾患の概略や現在の発症率・有病率の傾向、全体的な治験件数の動向見通し、薬物クラス別の治験/市場規模見通し、主な治療薬の治験動向と潜在的な市場規模、といった情報を取りまとめてお届けいたします。

目次

第0章 AMLエグゼクティブサマリー

第1章 急性骨髄性白血病 (AML) の概要

  • AMLの背景
  • AMLの定義
  • AMLの症状
  • AML:WHOによる分類方法と、病期分類システム

第2章 AMLの診断

  • AMLの変異パターン
  • AMLの発症頻度と、成人におけると遺伝子変異の臨床的意義

第3章 AMLの疫学

  • G7諸国におけるAMLの疫学
  • AMLの発症件数の予測 (2030年まで)

第4章 AML:上市済み製品の現在の情勢

  • AMLの治療アルゴリズム (2020年:適合/不適合)
  • AMLの上市済み治療薬
  • AMLの診療に基づくアンメットニーズ

第5章 AMLの新たな治療法の情勢

  • AMLの新規治療薬の情勢:治療クラス別・作用機序別
  • 抗体薬物複合体 (ADC)、三重特異性抗体、二重特異性抗体、モノクローナル抗体
  • CAR-T細胞療法、T細胞療法、細胞療法、CAR-T(NK細胞)
  • 小分子
  • ワクチンとワクチンアジュバント
  • その他
  • AMLの主な比較分析(第III相)
  • AMLの治験情勢
  • 第III相、第II相、第I相
  • 国際会議の結果:概略 - AML EHA 2020、ASCO 2020、ASH 2019
  • AML治療薬の特性:LOT (治療法の選択段階)、患者の区分 (新規診断患者、突然変異性、再発性/難治性、適合/不適合)、作用機序、治験の段階、企業など
目次

Acute myelogenous leukemia (AML) Disease Landscape provides comprehensive market intelligence with epidemiology, keen insight into current treatment paradigms, in-depth pipeline coverage ( ~ 470 unique industry-sponsored studies) and clinical trial landscape supported by detailed recent results (~ 96 trial's results) from ASH 2019, ASCO 2020 and EHA 2020. The drugs are further classified according to the class of therapies: antibody drug conjugates, bispecific antibodies, tri-specific and monoclonal antibodies, CAR-T therapies & T cells therapies, vaccines, small molecules and others.

Acute myelogenous leukemia (AML) is a cancer that starts in blood stem cells. Commonly known as acute myeloid leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute granulocytic leukemia or acute non-lymphocytic leukemia (ANLL). Once diagnosed, AML disease is described as untreated, in remission, or recurrent. The executive deck covers the AML overview, definition, diagnosis, percentage of patients based on mutation frequency, and treatment practice related unmet needs.

Acute Myeloid Leukemia (AML) Epidemiology

  • The global incidence of AML is increasing 105,842 cases in 2019 to 119,247 in 2030, with a potential growth rate of 1.09% during the forecast period.
  • Cases of AML with diagnosed incidence in the US will increase to 21,530 by 2030
  • Cases of AML with diagnosed incidence in the EU will increase to 17,139 by 2030
  • AML Five-year survival rate is 28.7% in the US and 24% in the EU

Acute Myeloid Leukemia (AML) Current Treatment Landscape

The main treatment for most types of AML is chemotherapy, along with a targeted therapy drug and followed by a stem cell transplant. In patients who are under 60 years old, induction chemotherapy for AML is given. The goal of induction therapy is to induce a remission, usually defined as less than 5% blast cells found in the bone marrow. Once remission is achieved, consolidation therapy is given. In this phase, chemotherapy is continued for 4-5 more cycles (4-6 months), generally with cytarabine alone, in higher doses.

The treatment of those over the age of 60 include recently approved new targeted therapies for AML-i.e., venetoclax, glasdegib, gemtuzumab, gemtuzumab, enasidenib, mitoxantrone, decitabine, azacitidine, midostaurin and clofarabine .

Changing Treatment Landscape of AML: Clinical Trial Pipeline coverage

  • ~ 470 unique industry-sponsored studies have been covered for acute myeloid leukemia, of which Phase I studies are 192, Phase I / II studies are 128, Phase II studies are 97, Phase II studies / III are 4 and Phase III studies are 49
  • Recent AML results are covered from ASH 2019, ASCO 2020 and EHA 2020 conferences (~ 96 trial's results) .
  • Of all the studies, the drugs under consideration for the first line were ~ 81, the second line were ~ 247 and the second line + were 86 and ~ 81 studies were not specified.
  • Specific mutation studies show that there are approximately 18 studies for IDH-related mutations, 25 studies for FLT-3 mutations (of which 11 studies related to FLT-3 ITD mutations were 11).
  • ~ 175 studies are being tested for refractory and relapsing patients while ~ 46 studies are being tested for patients with newly diagnosed AML
  • The drugs are further classified according to the class of therapies: antibody drug conjugates, bispecific antibodies, tri-specific and monoclonal antibodies, CAR-T therapies and T cells therapies, vaccines, small molecules and others.

Table of Contents

Section 0: AML Executive Summary

Section 1: Acute Myeloid Leukemia Overview

  • AML Disease Background
  • AML Disease Definition
  • AML Symptoms
  • AML WHO Classification and Staging System

Section 2: AML Diagnosis

  • AML Mutation Patterns
  • AML Frequency and Clinical Significance of Gene Mutations in Adults

Section 3: AML Epidemiology

  • Epidemiology of AML by G7 Countries
  • Forecasted AML Cases to 2030

Section 4: AML Current Marketed Landscape

  • AML Treatment Algorithm 2020 [Fit & Unfit]
  • AML Marketed Therapies
  • AML Treatment Practice based Unmet Needs

Section 5: AML Emerging Therapy Landscape

  • AML Emerging Landscape by Class of Therapies & Mechanism of Action
  • ADCs, Trispecific Antibodies, Bi-specific Antibodies & Monoclonal Antibodies
  • CAR-T Cell Therapies, T-Cell therapies, Cell therapy & CAR-T (NK Cells)
  • Small Molecules
  • Vaccines and vaccine Adjuvant
  • Others
  • AML Key Comparative Analysis (Phase III)
  • Clinical Trials Landscape of AML
  • Phase III, Phase II & Phase I
  • AML EHA 2020, ASCO 2020, ASH 2019 Conference Results covered
  • AML drugs covered by Line of Therapies (LOT), Patient Segment (Newly Diagnosed, Mutation specific, Relapsed or Refractory & Fit or Unfit), Mechanism of Action, Trial Phase, Company and other details
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.